This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Nov 21, 2025
•
9 min read
🧬 Moderna secures $1.5B loan facility - targeting breakeven by 2028 amid pipeline reevaluation, Aspen Neuroscience raises $115M Series C for Parkinson's cell therapy development, Cassidy Bio launches with $8M seed funding to develop AI-driven gene editing platform, GSK + Quotient Therapeutics + ProFound Therapeutics partner on respiratory + liver disease targets in up to $7B potential deal value, Merck KGaA + Valo Health partner on Parkinson's target discovery using AI platform in up to $3B potential deal, Regeneron's Eylea HD wins FDA approval for retinal vein occlusion macular edema and monthly dosing expansion
Nov 20, 2025
10 min read
🧬 Eli Lilly opens fourth US Gateway Labs biotech incubator facility in Philadelphia, Novartis plans $771M North Carolina manufacturing hub expansion to add 700 jobs by 2028, Rafa Laboratories awarded $186M BARDA contract for intramuscular tranexamic acid injection development, Profluent raises $106M Series B, AI-driven protein design for therapeutics and agriculture, GSK + LTZ Therapeutics partner on myeloid cell engagers for cancer with $50M upfront, Bayer's Hyrnuo (sevabertinib) receives FDA accelerated approval targeting HER2-mutated non-small cell lung cancer, AstraZeneca + Sun Pharma partner to expand hyperkalaemia therapy access in India via dual branding, FDA grants full approval for Amgen's IMDELLTRA (tarlatamab) targeting extensive stage small cell lung cancer
Nov 19, 2025
🧬 Regeneron invests $2B to convert former magazine factory into drug manufacturing plant in New York state, CSL pledges $1.5B investment to expand US plasma manufacturing capabilities over five years, Arrowhead Pharmaceuticals wins first FDA approval for Redemplo targeting familial chylomicronemia syndrome via RNA interference, Lifordi raises undisclosed strategic funding from Sanofi for ADC rheumatoid arthritis therapy, Vanda Pharmaceuticals' tradipitant (neurokinin-1 antagonist) reduces Wegovy-induced vomiting in Ph2 trial, Merck & Co.'s Winrevair (sotatercept) meets Ph2 endpoint for heart failure with preserved ejection fraction treatment, GSK + Fleming Initiative launch £45M ($59.2M) AI-powered antimicrobial resistance research partnership
Nov 18, 2025
🧬 J&J acquires Halda Therapeutics for $3B cash to boost cancer pipeline toward $50B sales target, Solve Therapeutics raises $120M Series funding to advance ADC pipeline with novel linker technology, Artios Pharma raises $115M Series D to advance oncology pipeline including pancreatic/colorectal cancer treatments, Merus + Halozyme collaborate on subcutaneous petosemtamab formulation with upfront payment and royalties, Bayer officially opens Beijing incubator + names Puhe BioPharma and Youngen Technology as initial occupants, Jazz Pharmaceuticals' Ziihera (zanidatamab) hits Ph3 goals in HER2-positive gastroesophageal adenocarcinoma, FDA streamlines biosimilar approvals to cut $100M development costs though patent challenges remain
Nov 17, 2025
8 min read
🧬 Sofinnova Partners raises $750M flagship fund, early-stage biotech medtech investments, Medicxi closes $579M sixth fund for asset-centric biotech investing, Merck & Co. acquires Cidara Therapeutics for $9.2B to gain late-stage universal flu prevention drug CD388, Eisai presents 48-month lecanemab (leqembi) data showing sustained benefits in early Alzheimer's disease patients, FDA approves Henlius' Poherdy (pertuzumab-dpzb) - first interchangeable biosimilar to Roche's Perjeta for HER2-positive breast cancer, PRISM BioLab achieves initial milestone + milestone payment in oncology drug discovery collaboration with Ono Pharmaceutical using PepMetics technology
Nov 14, 2025
7 min read
🧬 Pfizer officially closes $9.2 billion Metsera acquisition after winning bidding war against Novo Nordisk, T-Therapeutics raises $91M Series A extension to advance TCR-CD3 bispecifics for cancer/autoimmune, 4TEEN4 raises €55M ($63.75M) Series C for cardiogenic shock antibody procizumab development, Third Arc Bio + Adagene partner on cancer T cell engagers using SAFEbody technology - $5M upfront + $840M biobucks, Day One acquires struggling ADC developer Mersana for $129M upfront in milestone-heavy deal, Kura Oncology's Komzifti (ziftomenib) receives FDA approval for NPM1-mutant acute myeloid leukemia treatment
Nov 13, 2025
🧬 ABL Bio + Eli Lilly partner on blood-brain barrier platform with $40M upfront + $2.562B biobucks, Indivi raises CHF15M ($18.7M) to determine precision medicine biomarkers for Alzheimer's drug development, Syrna Therapeutics emerges from stealth with covalent translation inhibitors targeting disease-causing mRNA proteins, Novartis plans approval filing for GanLum malaria drug following Ph3 success in parasitic infection treatment, Alkermes reports Ph2 success for alixorexton targeting orexin 2 receptor in narcolepsy type 2 - advancing to Ph3, Novo Nordisk slashes Wegovy weight-loss drug prices up to 33% in India amid increased competition
Nov 12, 2025
🧬 Pfizer launches Ph3 trials of PF-08634404 (PD-1xVEGF bispecific) targeting non-small cell lung cancer as part of strategy to replace Keytruda, Mallinckrodt and Endo complete $6.7B merger + rebrand as Keenova and spin off Par Health generics business, Vor Bio raises $100M public offering, transforming autoimmune disease treatment, Glenmark's Ryaltris (olopatadine/mometasone furoate) wins China NMPA approval for moderate to severe allergic rhinitis treatment, UK unveils roadmap to replace animal testing with AI + 3D models
Nov 11, 2025
15 min read
🧬 Pfizer beats Novo Nordisk with $10B Metsera acquisition after fierce bidding war and anti-trust concerns, Eli Lilly + SanegeneBio partner on $1.2B RNAi metabolic disease platform with targeted delivery technology, Onchilles raises $25M Series A1 for dual-action cancer biologics targeting ELANE pathway
Nov 7, 2025
🧬 Novo Nordisk raises Metsera bid again after Pfizer matches $10B offer in obesity drug acquisition battle, FDA approves Johnson & Johnson's Darzalex Faspro (daratumumab) for high-risk smoldering multiple myeloma following Ph3 trial, AstraZeneca acquires obesity startup SixPeaks Bio for $170M - targeting muscle-preserving weight loss drugs, Axsome acquires AstraZeneca epilepsy candidate AXS-17 through Baergic Bio acquisition (Avenue Therapeutics subsidiary) in up to $83M deal, Cencora allocates $1B over five years to expand US drug distribution with new facilities, Accipiter Biosciences launches with $12.7M Seed - developing de novo protein therapies for complex diseases, Renasant Bio launches with $54.5M seed funding to develop ADPKD small molecule treatments, Forbion closes €200M ($229.9M) BioEconomy Fund I - investing in sustainable biotechnologies
Nov 6, 2025
🧬 Braveheart Bio launches with $185M to take on Bristol Myers Squibb’s heart drug in hypertrophic cardiomyopathy, Eli Lilly + XtalPi expand AI partnership to bispecific antibodies in up to $345M deal, Novo Nordisk presents Ph3 data showing oral Wegovy (semaglutide) reduces cardiovascular risk factors in obesity, FTC warns Novo Nordisk's Metsera acquisition bid may circumvent required antitrust premarket review process, AstraZeneca invests additional $136M in Chinese inhalants plant - bringing total Qingdao investment to $886M, Evommune raises $150M IPO to develop drugs for immune conditions like hives and dermatitis, Kelonia Therapeutics + Johnson & Johnson collaborate on in vivo CAR-T therapies using iGPS platform
Nov 5, 2025
🧬 Novo Nordisk raises Metsera buyout bid to $10B - beating Pfizer's revised $8.1B offer, Azalea Therapeutics launches from Doudna origins with $82M and in vivo CAR-T therapy ambitions (via genome editing delivery tech), Neok Bio debuts with $75M Series A to advance bispecific ADCs targeting dual cancer markers, Hengrui Pharma + Kailera Therapeutics report positive Ph3 data for HRS9531 dual GLP-1/GIP agonist in obesity treatment, Blackstone Life Sciences signs royalty deal with Merck & Co. - paying $700M upfront in exchange for portion of sacituzumab tirumotecan future sales, Meitheal Pharmaceuticals receives FDA approval for CONTEPO (fosfomycin) targeting complicated urinary tract infections including acute pyelonephritis, Compass Pathways accelerates COMP360 commercial timeline for treatment-resistant depression following positive FDA meeting
